NANO-VAC Research Group, Department of Chemistry and Pharmaceutical Technology, University of Navarra, Spain.
Department of Pharmaceutical, Chemical and Environmental Sciences, University of Greenwich, Chatham Maritime, UK.
Eur J Pharm Sci. 2019 Feb 1;128:81-90. doi: 10.1016/j.ejps.2018.11.025. Epub 2018 Nov 23.
Thiamine-coated nanoparticles were prepared by two different preparative methods and evaluated to compare their mucus-penetrating properties and fate in vivo. The first method of preparation consisted of surface modification of freshly poly(anhydride) nanoparticles (NP) by simple incubation with thiamine (T-NPA). The second procedure focused on the preparation and characterization of a new polymeric conjugate between the poly(anhydride) backbone and thiamine prior the nanoparticle formation (T-NPB). The resulting nanoparticles displayed comparable sizes (about 200 nm) and slightly negative surface charges. For T-NPA, the amount of thiamine associated to the surface of the nanoparticles was 15 μg/mg. For in vivo studies, nanoparticles were labelled with either Tc or Lumogen® Red. T-NPA and T-NPB moved faster from the stomach to the small intestine than naked nanoparticles. Two hours post-administration, for T-NPA and T-NPB, >30% of the given dose was found in close contact with the intestinal mucosa, compared with a 13.5% for NP. Interestingly, both types of thiamine-coated nanoparticles showed a greater ability to cross the mucus layer and interact with the surface of the intestinal epithelium than NP, which remained adhered in the mucus layer. Four hours post-administration, around 35% of T-NPA and T-NPB were localized in the ileum of animals. Overall, both preparative processes yielded thiamine decorated carriers with similar physico-chemical and biodistribution properties, increasing the versatility of these nanocarriers as oral delivery systems for a number of biologically active compounds.
采用两种不同的制备方法制备了包被硫胺素的纳米颗粒,并对其进行了评价,以比较它们的穿透黏液特性和体内命运。第一种制备方法包括通过简单地与硫胺素(T-NPA)孵育来对新制备的聚(酸酐)纳米颗粒(NP)进行表面改性。第二种方法侧重于在形成纳米颗粒之前制备和表征聚(酸酐)主链与硫胺素之间的新型聚合物缀合物(T-NPB)。所得纳米颗粒显示出相当的尺寸(约 200nm)和略微负的表面电荷。对于 T-NPA,与纳米颗粒表面结合的硫胺素的量为 15μg/mg。对于体内研究,纳米颗粒用 Tc 或 Lumogen® Red 标记。与裸纳米颗粒相比,T-NPA 和 T-NPB 从胃更快地移动到小肠。给药后 2 小时,T-NPA 和 T-NPB 的 30%以上的给定量被发现与肠黏膜紧密接触,而 NP 的给定量为 13.5%。有趣的是,两种类型的包被硫胺素的纳米颗粒都显示出比 NP 更强的穿过黏液层并与肠上皮表面相互作用的能力,而 NP 则仍附着在黏液层中。给药后 4 小时,约 35%的 T-NPA 和 T-NPB 定位于动物的回肠中。总体而言,两种制备工艺都得到了具有相似物理化学和分布特性的包被硫胺素载体,增加了这些纳米载体作为许多生物活性化合物的口服递药系统的多功能性。
Eur J Pharm Biopharm. 2015-11
J Nanosci Nanotechnol. 2006
Int J Pharm. 2002-8-21
Molecules. 2005-1-31
J Control Release. 2005-8-18
Food Sci Nutr. 2023-11-9
Nanomaterials (Basel). 2023-2-22
Int J Mol Sci. 2022-8-10
Int J Pharm X. 2021-11-9
Drug Deliv Transl Res. 2021-4